Relevant bibliographies by topics / Bromocriptine

Academic literature on the topic 'Bromocriptine'

Author: Grafiati
Published: 4 June 2021
Last updated: 25 April 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Bromocriptine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Bromocriptine"

1

Framnes-DeBoer, Sarah N., Ellen Bakke, Suma Yalamanchili, Hannah Peterson, Darleen A. Sandoval, Randy J. Seeley, and Deanna M. Arble. "Bromocriptine improves glucose tolerance independent of circadian timing, prolactin, or the melanocortin-4 receptor." American Journal of Physiology-Endocrinology and Metabolism 318, no. 1 (January 1, 2020): E62—E71. http://dx.doi.org/10.1152/ajpendo.00325.2019.

Full text
Abstract:
Bromocriptine, a dopamine D2 receptor agonist originally used for the treatment of hyperprolactinemia, is largely successful in reducing hyperglycemia and improving glucose tolerance in type 2 diabetics. However, the mechanism behind bromocriptine’s effect on glucose intolerance is unclear. Here, we tested three hypotheses, that bromocriptine may exert its effects on glucose metabolism by 1) decreasing prolactin secretion, 2) indirectly increasing activity of key melanocortin receptors in the central nervous system, or 3) improving/restoring circadian rhythms. Using a diet-induced obese (DIO) mouse model, we established that a 2-wk treatment of bromocriptine is robustly effective at improving glucose tolerance. We then demonstrated that bromocriptine is effective at improving the glucose tolerance of both DIO prolactin-deficient and melanocortin-4 receptor (MC4R)-deficient mice, pointing to bromocriptine’s ability to affect glucose tolerance independently of prolactin or MC4R signaling. Finally, we tested bromocriptine’s dependence on the circadian system by testing its effectiveness in environmental (e.g., repeated shifts to the light-dark cycle) and genetic (e.g., the Clock mutant mouse) models of circadian disruption. In both models of circadian disruption, bromocriptine was effective at improving glucose tolerance, indicating that a functional or well-aligned endogenous clock is not necessary for bromocriptine’s effects on glucose metabolism. Taken together, these results do not support the role of prolactin, MC4R, or the circadian clock as integral to bromocriptine’s underlying mechanism. Instead, we find that bromocriptine is a robust diabetic treatment and resilient to genetically induced obesity, diabetes, and circadian disruption.
APA, Harvard, Vancouver, ISO, and other styles
2

&NA;. "Bromocriptine." Reactions Weekly &NA;, no. 1199 (April 2008): 14. http://dx.doi.org/10.2165/00128415-200811990-00034.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

&NA;. "Bromocriptine." Reactions Weekly &NA;, no. 439 (February 1993): 5. http://dx.doi.org/10.2165/00128415-199304390-00017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

&NA;. "Bromocriptine." Reactions Weekly &NA;, no. 454 (June 1993): 6. http://dx.doi.org/10.2165/00128415-199304540-00020.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

&NA;. "Bromocriptine." Reactions Weekly &NA;, no. 458 (July 1993): 5. http://dx.doi.org/10.2165/00128415-199304580-00016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

&NA;. "Bromocriptine." Reactions Weekly &NA;, no. 428 (November 1992): 5. http://dx.doi.org/10.2165/00128415-199204280-00016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

&NA;. "Bromocriptine." Reactions Weekly &NA;, no. 432 (December 1992): 6. http://dx.doi.org/10.2165/00128415-199204320-00024.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

&NA;. "Bromocriptine." Reactions Weekly &NA;, no. 283 (January 1990): 4. http://dx.doi.org/10.2165/00128415-199002830-00008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

&NA;. "Bromocriptine." Reactions Weekly &NA;, no. 288 (February 1990): 6. http://dx.doi.org/10.2165/00128415-199002880-00013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

&NA;. "Bromocriptine." Reactions Weekly &NA;, no. 289 (February 1990): 5. http://dx.doi.org/10.2165/00128415-199002890-00012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Bromocriptine"

1

LE, POMMELET CHRISTOPHE. "Sandostatine et bromocriptine dans l'acromegalie." Aix-Marseille 2, 1992. http://www.theses.fr/1992AIX20840.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pagnacco, Marie. "Le traitement des prolactinomes par bromocriptine retard." Université Louis Pasteur (Strasbourg) (1971-2008), 1992. http://www.theses.fr/1992STR1M031.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

BOSSUT, JEAN-LOUIS. "Traitement des prolactinomes par la bromocriptine injectable : a propos d'une etude retrospective sur 23 patients." Lille 2, 1994. http://www.theses.fr/1994LIL2M307.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lucia, Christine. "Pleuropneumopathies à la bromocriptine : discussion sur un cas." Montpellier 1, 1991. http://www.theses.fr/1991MON11209.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

BERTHET, EVELYNE. "Les macroprolactinomes et leur traitement : role de la bromocriptine." Lyon 1, 1989. http://www.theses.fr/1989LYO1M486.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Odenthal, Maria Esther. "Uso da bromocriptina e da dexametasona na interrupção da gestação em cadelas." Universidade Federal de Viçosa, 2003. http://locus.ufv.br/handle/123456789/5170.

Full text
Abstract:
Made available in DSpace on 2015-03-26T13:47:20Z (GMT). No. of bitstreams: 1 texto completo.pdf: 235255 bytes, checksum: e59ffc4b4d93eb2387e5b1f9aaefaf2a (MD5) Previous issue date: 2003-12-16
With the goal of evaluating the efficacity of bromocriptine and dexametazone, 30 mongrel bitches, with more than 35 days of pregnancy confirmed by ultrasonography, clinicaly healthy, with weights varying between 10 and 30 kgs, were divided in three groups: Group 1 - Underwent treatment with bromocriptine for 6 days with a dosage of 0,03 mg/kg every 12 hours; Group 2 Underwent treatment with dexametasone for 10 days with a dosage of 0,2 mg/kg every 12 hours; Group 3 control. The results demonstrated that both the animals treated with bromocriptine as well as those treated with dexametasone had their pregnancies interrupted in 90% of the cases. In the conditions in which the present experiment was made, no serious endometrial alterations, with endangerment of uterine phisiology, were observed. It was verified that the abortion happens later in the group treated with dexametasone, where the phoetus expulsion may occur up to the 10th day after the treatment.
Objetivando avaliar o efeito abortivo de bromocriptina e da dexametasona, 30 cadelas sem raça definida, com mais de 35 dias de gestação, confirmada por ultrasonografia, clinicamente sadias, com peso variando entre 10 e 30 kg foram separadas em três grupos, a saber: Grupo 1 - Submetidas ao tratamento com bromocriptina durante 6 dias na dose de 0,01 mg/kg a cada 12 horas; Grupo 2 - Tratadas com dexametasona durante 10 dias na dose de 0,02 mg/kg a cada 12 horas; Grupo 3- Controle. Os resultados demonstraram que tanto os animais tratados com bromocriptina, como aqueles tratados com dexametasona tiveram suas gestações interrompidas em 90% dos casos. Na condição em que foi realizado o presente experimento, não foram observadas alterações endometriais graves, que pudessem comprometer a fisiologia uterina. Verificou-se que o abortamento é mais tardio no grupo tratado com dexametasona com a expulsão do feto pode ocorrer até o 10o dia após o início do tratamento.
APA, Harvard, Vancouver, ISO, and other styles
7

MARTINET, JEAN-PIERRE. "Adjonction de bromocriptine a un traitement par neuroleptique chez des patients schizophrenes resistants." Rennes 1, 1992. http://www.theses.fr/1992REN1M014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

SARRAIL, ERIC. "Boromocriptine et hyponatremie." Toulouse 3, 1992. http://www.theses.fr/1992TOU31035.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

COUSINIE, VERONIQUE. "Comparaison de la bromocriptine et de la levodopa dans le traitement de premiere intention de la maladie de parkinson : comparaison des effets secondaires de la leovodpa chez des patients traites par levodopa ou bromocriptine plus levodopa." Toulouse 3, 1991. http://www.theses.fr/1991TOU31059.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Brue, Thierry. "La prolactine humaine, aspects physiopathologiques ; resistance des prolactinomes a la bromocriptine et heterogeneite moleculaire de la prolactine." Aix-Marseille 2, 1995. http://www.theses.fr/1995AIX20652.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Bromocriptine"

1

Publications, ICON Health. Bromocriptine - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References. ICON Health Publications, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

1933-, Fahn Stanley, ed. Parlodel® (bromocriptine mesylate) in the early management of Parkinson's disease: Excerpts from Recent developments in Parkinson's disease, volume 2. Florham Park, N.J: Macmillan Healthcare Information, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Shorter, Edward, and Max Fink. The Neuroleptic Malignant Syndrome. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190881191.003.0009.

Full text
Abstract:
Reports of fatal febrile, hypertensive, tachycardic neurotoxic cases followed quickly on the introduction of potent new neuroleptic drugs in the 1970s. Patients became mute, rigid, posturing, and staring, showing the signs of catatonia. Labeled the neuroleptic malignant syndrome (NMS), attention was first given to neuroleptic blockade of dopamine receptors as the cause, but treatments with dopamine agonists (bromocriptine) and muscle relaxants (dantrolene) offered little benefit. When catatonia was recognized, treatments with benzodiazepines (lorazepam, diazepam) and induced seizures (electroshock, ECT) led to clinical relief and the saving of lives. The recognition of NMS as catatonia stimulated a revision of the century-long view of catatonia as a form of schizophrenia, with calls for catatonia to be considered independent of schizophrenia.
APA, Harvard, Vancouver, ISO, and other styles
4

Sliwa, Karen, and Denise Hilfiker-Kleiner. Peripartum cardiomyopathy. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0374.

Full text
Abstract:
Pregnancy-related heart disease is increasing worldwide and peripartum cardiomyopathy (PPCM) is an important contributor to early (<42 days postpartum) and late (up to 1 year postpartum) maternal death. PPCM is an idiopathic form of cardiomyopathy, presenting with heart failure secondary to left ventricular dysfunction towards the end of pregnancy, or in the months following delivery, where no other cause of heart failure is identified. It is a diagnosis of exclusion. Incidence and prognosis varies according to geography and is likely due to multiple factors. The recent specific pathophysiological hypothesis which states that the oxidative stress–cathepsin D-16 kDa prolactin cascade plays a key role in the development of PPCM in experimental models and in humans suggests that a therapeutic approach involving blockade of this pathway with bromocriptine may be a novel disease-specific approach. Despite ongoing research, numerous uncertainties regarding the incidence, pathophysiology, treatment, and prognosis of PPCM patients remain, indicating the need for further investigation. The establishment of the international registry on PPCM, under the umbrella of the EuroObservational research programme, will provide novel information and address many uncertainties.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Bromocriptine"

1

Libon, David J. "Bromocriptine." In Encyclopedia of Clinical Neuropsychology, 647. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-57111-9_1632.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Libon, David J. "Bromocriptine." In Encyclopedia of Clinical Neuropsychology, 459–60. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-0-387-79948-3_1632.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Tyrer, Peter J., Mark Slifstein, Joris C. Verster, Kim Fromme, Amee B. Patel, Britta Hahn, Christer Allgulander, et al. "Bromocriptine." In Encyclopedia of Psychopharmacology, 251. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_1778.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Libon, David J. "Bromocriptine." In Encyclopedia of Clinical Neuropsychology, 1. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-56782-2_1632-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

von Werder, K. "Bromocriptine Treatment of Acromegaly." In Sandostatin® in the Treatment of Acromegaly, 45–52. Berlin, Heidelberg: Springer Berlin Heidelberg, 1988. http://dx.doi.org/10.1007/978-3-642-73694-0_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ginat, Daniel Thomas. "Bromocriptine (Parlodel) and Cabergoline (Dostinex)." In Neuroimaging Pharmacopoeia, 189–96. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-12715-6_24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Horowski, Reinhard. "Bromocriptine for Treating Parkinson’s Disease." In NeuroPsychopharmacotherapy, 1–5. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-319-56015-1_222-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lieberman, A. N., and M. Goldstein. "Update on Bromocriptine in Parkinson’s Disease." In Drugs for the Treatment of Parkinson’s Disease, 443–58. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-73899-9_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ali, Shamsa, and Vivian Fonseca. "Innovative therapies in diabetes: colesevelam and bromocriptine." In International Textbook of Diabetes Mellitus, 758–64. Chichester, UK: John Wiley & Sons, Ltd, 2015. http://dx.doi.org/10.1002/9781118387658.ch50.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mattioli, M., and E. Seren. "Effects of Bromocriptine Treatment During Lactational Anestrus in Pigs." In Endocrine Causes of Seasonal and Lactational Anestrus in Farm Animals, 165–78. Dordrecht: Springer Netherlands, 1985. http://dx.doi.org/10.1007/978-94-009-5026-9_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Bromocriptine"

1

Tang, Chao, and Chiyuan Ma. "(A221) Bromocriptine and Cabergoline Induces Cell Death in Prolactinoma Cells via the ERK/EGR1 and AKT/MTOR Pathway Respectively." In 29th Annual Meeting North American Skull Base Society. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1679636.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

"SÍNDROME NEUROLÉPTICO MALIGNO Y TRASTORNO POR CONSUMO DE ALCOHOL: A PROPÓSITO DE UN CASO." In 23° Congreso de la Sociedad Española de Patología Dual (SEPD) 2021. SEPD, 2021. http://dx.doi.org/10.17579/sepd2021p125v.

Full text
Abstract:
INTRODUCCIÓN: el síndrome neuroléptico maligno es una emergencia vital neurológica asociada al uso de antipsicóticos. Se ha relacionado a condiciones como la catatonía o la agitación extrema, y el diagnóstico se basa en la tétrada siguiente: cambios en el nivel de conciencia, rigidez muscular generalizada, hipertermia y disautonomía. En la analítica aparece una CK mayor de 1.000. El tratamiento consiste en medidas de soporte y la retirada del agente causante, aunque existen fármacos específicos como el Dantroleno o la Bromocriptina. El siguiente caso muestra un paciente con un diagnóstico previo de trastorno por consumo de alcohol al que se diagnostica SNM. CASO CLÍNICO: se trata de un varón de 30 años, bebedor de grandes cantidades de alcohol diariamente. Como antecedentes solo consta un ingreso por psicosis. Es trasladado a urgencias por alteraciones conductuales, y se le administran AP a altas dosis. Los tóxicos en orina son positivos a BZD, y la sospecha inicial es de Delirium Tremens. A los días de ingreso su estado empeora, disminuyendo el nivel de conciencia y apareciendo HTA, fibrilación auricular y fiebre de 39º, así como una CK de hasta 1.400. Finalmente aparece rigidez en rueda dentada, se procede al diagnóstico de SNM y se trata al paciente con Bromocriptina y Dantroleno, con mejoría franca al día siguiente. DISCUSIÓN: existen pocos casos reportados en la literatura sobre SNM, y este número es menor aún en el caso de un trastorno por consumo de alcohol concomitante. Sería interesante indagar en la relación que tienen estas dos entidades y como influyen en el pronóstico del paciente. Además, aunque el reporte de casos y la experiencia clínica sugieran disminución de la mortalidad con tratamiento específico, no existen ensayos controlados que hayan probado la eficacia de ningún fármaco para el SNM, siendo necesaria más investigación al respecto.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Bromocriptine' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography